eurofins | Discovery Services

Certificate of Analysis

DAPK2, active

(Recombinant enzyme expressed in Sf21 insect cells)
Item # 14-657, 14-657-K, 14-657M
Parent Lot # 28637U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: *N*-terminal GST-tagged, recombinant, human, full length DAPK2, expressed by baculovirus in Sf21 insect cells. Purified using glutathione agarose. Purity 78% by SDS-PAGE and Coomassie blue staining. MW = 70.6kDa.

Specific Activity (Parent lot# 28637U): 105U/mg, where one unit of DAPK2, active activity is defined as 1nmol phosphate incorporated into 250µM (KKLNRTLSFAEPG) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 0.937mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS

Quality Control Testing

Kinase Assay: 9.32–117.5ng of this lot of enzyme phosphorylated 250µM (KKLNRTLSFAEPG) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as DAPK2 with the translated native sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of DAPK2, active.

Eurofins Pharma Discovery Services UK Limited
Gemini Crescent
Dundee Technology Park
DUNDEE
DD2 1SW United Kingdom
T | +44 (0)1382 561600
F | +44 (0)1382 561601
www.eurofins.com/pharmadiscovery

eurofins | Discovery Services

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS-NaOH pH7.0, 1mM EDTA.
2. **(KKLNRTLSFAEPG):** Use at a final assay concentration of 250µM. Make a 2.5µM stock. Add 2.5µl of stock per assay point.
3. **$CaCl_2$:** Use at a final assay concentration of 500µM. Make a 5mM stock. Add 2.5µl of stock per assay point.
4. **Calmodulin:** Use at a final concentration of 1µM. Make a 0.3mg/ml stock. Add 1.33µl of stock per assay point.
5. **DAPK2, active:** Dilute with 20mM MOPS-NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 9.32–117.5ng per assay point.
6. **[γ-^{33}P]ATP:** 2.5 x magnesium acetate/[γ-^{33}P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-^{33}P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of **(KKLNRTLSFAEPG)**.
3. Add **2.5µl (9.32–117.5ng) DAPK2, active**.
4. Add 2.5µl of 5mM $CaCl_2$.
5. Add 1.33µl of 0.3mg/ml calmodulin.
6. Add 1.17µl of dH_2O.
7. Add 10µl of diluted [γ-^{33}P]ATP mixture.
8. Incubate for 10 minutes at 30°C.
9. Stop the reaction by adding 5µl of 3% phosphoric acid.
10. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
11. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
12. Wash the filtermat once for 2 minutes with methanol.
13. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
14. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

eurofins | Discovery Services

Certificate of Analysis

DAPK2 Sequence Information

Protein Human DAPK2

Tags *N*-terminal GST

Native sequence M237 of the recombinant protein is equivalent to M1 of human DAPK2

Accession number GenBank NM_014326

Recombinant DAPK2 amino acid sequence:

```
  1 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
 61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LEVLFQGPEF KGLRRQMFQA
241 SMRSPNMEPF KQQKVEDFYD IGEELGSGQF AIVKKCREKS TGLEYAAKFI KKRQSRASRR
301 GVSREEIERE VSILRQVLHH NVITLHDVYE NRTDVVLILE LVSGGELFDF LAQKESLSEE
361 EATSFIKQIL DGVNYLHTKK IAHFDLKPEN IMLLDKNIPI PHIKLIDFGL AHEIEDGVEF
421 KNIFGTPEFV APEIVNYEPL GLEADMWSIG VITYILLSGA SPFLGDTKQE TLANITAVSY
481 DFDEEFFSQT SELAKDFIRK LLVKETRKRL TIQEALRHPW ITPVDNQQAM VRRESVVNLE
541 NFRKQYVRRR WKLSFSIVSL CNHLTRSLMK KVHLRPDEDL RNCESDTEED IARRKALHPR
601 RRSSTS
```

Recombinant DAPK2 nucleotide sequence:

```
   1 atgtccccta tactaggtta ttggaaaatt aagggccttg tgcaacccac tcgacttctt
  61 ttggaatatc ttgaagaaaa atatgaagag catttgtatg agcgcgatga aggtgataaa
 121 tggcgaaaca aaaagtttga attgggtttg gagtttccca atcttcctta ttatattgat
 181 ggtgatgtta aattaacaca gtctatggcc atcatacgtt atatagctga caagcacaac
 241 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcggttttg
 301 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagtt
 361 gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcgttt atgtcataaa
 421 acatatttaa atggtgatca tgtaacccat cctgacttca tgttgtatga cgctcttgat
 481 gttgttttat acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa
 541 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca
 601 tggcctttgc agggctggca agccacgttt ggtggtggcg accatcctcc aaaatcggat
 661 ctggaagttc tgttccaggg gcccgaattc aaaggcctac gtcgacaaat gttccaggcc
 721 tcaatgagga gtccaaacat ggagccattc aagcagcaga aggtggagga cttttatgac
 781 atcggagagg agctggggag tggccagttt gccatcgtga agaagtgccg ggagaagagc
 841 acggggcttg agtatgcagc caagttcatc aagaagcggc agagccgggc gagccggcgc
 901 ggtgtgagcc gggaggagat cgagcgggag gtgagcatcc tgcggcaggt gctgcaccac
 961 aatgtcatca cgctgcacga cgtctatgag aaccgcaccg acgtggtgct catccttgag
1021 ctagtgtctg gaggagagct cttcgatttc ctggcccaga aggagtcact gagtgaggag
1081 gaggccacca gcttcattaa gcagatcctg gatggggtga actaccttca cacaaagaaa
1141 attgctcact ttgatctcaa gccagaaaac attatgttgt tagacaagaa tattcccatt
1201 ccacacatca agctgattga ctttggtctg gctcacgaaa tagaagatgg agttgaattt
1261 aagaatattt ttgggacgcc ggaatttgtt gctccagaaa ttgtgaacta cgagcccctg
1321 ggtctggagg ctgacatgtg gagcataggc gtcatcacct acatcctctt aagtggagca
1381 tccccctttcc tgggagacac gaagcaggaa acactggcaa atatcacagc agtgagttac
1441 gactttgatg aggaattctt cagccagacg agcgagctgg ccaaggactt tattcggaag
1501 cttctggtta aagagacccg gaaacggctc acaatccaag aggctctcag acacccctgg
1561 atcacgccgg tggacaacca gcaagccatg gtgcgcaggg agtctgtggt caatctggag
1621 aacttcagga agcagtatgt ccgcaggcgg tggaagcttt ccttcagcat cgtgtccctg
```

Certificate of Analysis

```
1681 tgcaaccacc tcacccgctc gctgatgaag aaggtgcacc tgaggccgga tgaggacctg
1741 aggaactgtg agagtgacac tgaggaggac atcgccagga ggaaagccct ccacccacgg
1801 aggaggagca gcacctccta a
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services.